Abstract -Placental ischemia is believed to be the initial event in the development of preeclampsia. Mitochondrial dysfunction is a cause of reactive oxygen species (ROS) generation and oxidative stress, however, there are not many studies examining the role of mitochondrial ROS in the pathology of preeclampsia. The purpose of this study was to not only examine the effect of placental ischemia on mitochondrial-mediated oxidative stress in reduced uterine perfusion pressure (RUPP) rat model of preeclampsia but to also examine the role of mitochondrial ROS in contributing to hypertension in response to placental ischemia. Female pregnant Sprague Dawley rats were used in this study. On gestational day 14, RUPP surgery was performed. On gestational day 19, blood pressure (mean arterial pressure) was measured, placentas and kidneys were collected from normal pregnant and RUPP rats and processed for mitochondrial respiration, ROS, and oxidative phosphorylation enzyme activities. Renal and placental complex activities, expressions and respiration rates were significantly reduced and mitochondrial ROS was increased in RUPP versus normal pregnant mitochondria. Mean arterial pressure was elevated in RUPP (n=6) compared with normal pregnant rats (n=5; 126±4 versus 103±4 mm Hg; P<0.05) and treatment with mitochondrial-specific antioxidants (MitoQ/MitoTEMPO) significantly reduced mean arterial pressure in RUPPs (n=5-10). Mitochondrial ROS was significantly elevated in endothelial cells incubated with RUPP serum compared from with normal pregnant rats, whereas serum from mito antioxidant-treated RUPP rats attenuated this response. Impaired mitochondrial function and vascular, placental, and renal mitochondrial ROS play an important role in hypertension and reduced fetal weight in response to placental ischemia during pregnancy. (Hypertension.
P reeclampsia affects 5% to 7% of all pregnancies in the United States [1] [2] [3] and is the leading cause of maternal and fetal death and morbidity. The mechanisms responsible for the pathogenesis of preeclampsia are unclear. Preeclampsia is characterized as hypertension with or without proteinuria after the 20th week of pregnancy and is associated with endothelial dysfunction, systemic vasoconstriction, inflammation, oxidative stress, and intrauterine growth restriction, and multiorgan dysfunction. [2] [3] [4] [5] Reactive oxygen species (ROS) are highly reactive free radicals, including superoxide (O − 2 ), hydrogen peroxide (H 2 O 2 ), hydroxyl radical (OH), and peroxynitrite (ONOO − ) that damage protein, DNA, and RNA within a cell causing cellular dysfunction and death. Oxidative stress is created by the imbalance between ROS and antioxidant defense of the cell. 6 During normal gestation, ROS production is reported to be increased; however, excessive ROS production has been reported in pathological states, such as preeclampsia. 7, 8 Studies reported that abnormal placentation and shallow trophoblast invasion stimulate placental oxidative stress, which leads to intravascular inflammatory response and endothelial dysfunction. 8 Although, multiple sources of ROS have been identified in the placenta, few studies have examined the role of mitochondrial dysfunction and ROS in the pathology of preeclampsia. Mitochondrial dysfunction causes a reduction in oxygen consumption and an increase in superoxide production. 9 Previous studies report reduced electron transport chain (ETC) activity and reduced antioxidant defense in human preeclamptic placentas. [10] [11] [12] [13] [14] [15] [16] However, neither mitochondrial dysfunction nor mitochondrial ROS has been examined. Additionally, we do not know the contribution mitochondrial dysfunction and mitochondrial ROS in the development of hypertension in response to placental ischemia. Moreover, the cause of mitochondrial dysfunction and ROS are unknown. Therefore, we sought to determine the role of placental ischemia to cause mitochondrial dysfunction and mitochondrial ROS not only in the placenta but in the kidney and from endothelial cells exposed to circulating factors from placental ischemic rats. Moreover, we wanted to evaluate the role of mitochondrial dysfunction and ROS in the development of hypertension in a valid model of preeclampsia. Thus, we hypothesized that placental ischemia causes mitochondrial dysfunction and increases mitochondrial ROS, which contributes to hypertension in response to placental ischemia. To test our hypothesis, we examined mitochondrial dysfunction and ROS in freshly isolated mitochondria from placentas and kidneys from the reduced uterine perfusion pressure model (RUPP) in the pregnant rat, the most reproducible rodent model of preeclampsia to date. Moreover, to determine whether mitochondrial ROS contributes to hypertension during pregnancy, we tested the effect of mitochondrial-specific antioxidants (MitoQ/ MitoTEMPO) in preventing the rise in blood pressure in RUPP rats compared with normal pregnant (NP) treated rats. We have previously shown that soluble factors from women with preeclampsia and the RUPP preclinical rat model of preeclampsia cause endothelial cell activation. 5 Therefore, we wanted to determine whether soluble factors stimulated in response to placental ischemia cause vascular mitochondrial ROS from endothelial cells, and if this could be corrected with mitochondrial-specific antioxidants.
Methods
The techniques and data that support the findings of this study are available from the corresponding author on reasonable request.
Animals
Pregnant Female Sprague Dawley rats purchased from Harlan Inc (Indianapolis, IN) were used in the present study. Rats were housed in a temperature-controlled room (23°C) with a 12:12 hour light/dark cycle with free access to standard rat chow and water. This study complied with guidelines of the University of Mississippi Medical Center, and the animals were handled according to the guiding principles published in the National Institutes of Health Guide for the Care of Animals and the Institutional Animal Care and Use Committee.
Role of Placental Ischemia to Cause Mitochondrial Dysfunction and ROS

RUPP Model
We used RUPP model, a well characterized and standard rat model of preeclampsia, to test our hypothesis in this study. Pregnant Sprague Dawley rats weighing ≈200 to 250 g were used. We have divided rats into 2 groups, NP and RUPP rats. Briefly, in RUPPs, reduction in blood flow to the uteroplacental unit was achieved by placing silver clips (0.203 mm ID) on the abdominal aorta (1 clip) above the iliac bifurcation and around the ovarian arteries (2 clips) on the both sides under isoflurane anesthesia on gestational day 14, which has been shown to reduce uterine blood flow in the gravid rat by ≈40%. Immediately after blood pressure measurement from NP and RUPP rats, blood and tissues were collected and processed for further experiments.
Isolation of Intact Mitochondria
Mitochondria from rat placenta or kidney were isolated using differential centrifugation method. 17 In brief, tissues were rinsed and homogenized with dounce homogenizer and the homogenate was centrifuged at 4000 rpm, 3 minutes at 4°C. The supernatant was centrifuged at 10 000 rpm, 10 minutes at 4°C, and the collected pellet was resuspended in Mito I buffer and centrifuged using the same settings. The final pellet was collected and resuspended in Mito II buffer and immediately used for respiration and ROS experiments. A small fraction of mitochondrial sample was flash frozen and stored at −80°C for ETC complex activity assays and Western blot (WB) analysis (a detailed method is described in the online-only Data Supplement).
Mitochondrial Enrichment
To determine the enrichment of mitochondria in our working isolated mitochondrial samples, we performed WB using antibodies for mitochondria or cytosolic proteins. Isolated mitochondrial sample or whole tissue lysate were run the gel and probed with VDAC (voltagedependent anion channel; mitochondrial marker) and GAPDH (cytosolic marker).
Measurement of ETC Expression by Immunoblotting
Expression of ETC complexes in placental RUPP (n=3) versus NP (n=3) or kidney RUPP (n=3) versus NP (n=3) mitochondria (complex I, II, III, IV, and V) was examined by WB (a detailed method is described in the online-only Data Supplement).
Measurement of ETC Activity
Complex I: Mitochondrial membranes were incubated with decyl ubiquinone, potassium cyanide, and antimycin A for 10 minutes in a quartz cuvette at 25°C. The reaction was started with the addition of NADH (nicotinamide adenine dinucleotide). The decrease in absorbance at 340 nm was recorded for 3 minutes. Rotenone sensitivity was measured by using rotenone in the assay.
Complex IV: Mitochondrial membranes were added to the chamber containing cytochrome c ascorbate and TMPD (N,N,N',N'-tetramethyl-p-phenylenediamine). The rate of oxygen consumption was measured using oxygraph (a detailed method is described in the online-only Data Supplement). Complex I: RUPP (n=4) versus NP (n=5). Complex IV: RUPP (n=6) versus NP (n=5).
Respiration in Isolated Mitochondria
Respiration in isolated mitochondria was measured using Oxygraph 2K. Basal, state 2, state 3, state 4, and uncoupled respiration rates were measured by emplying glutamate/malate, ADP, oligomycin, and FCCP (carbonyl cyanide-4-[trifluoromethoxy]phenylhydrazone), respectively. Rotenone and antimycin A were included to record nonmitochondrial respiration. The collected data were analyzed and expressed as pmol of oxygen consumed per second per milligram of mitochondrial protein (a detailed method is described in the onlineonly Data Supplement). Placental RUPP (n=5) versus NP (n=6) or renal RUPP (n=4) versus NP (n=4).
Mitochondrial ROS Production in Isolated Mitochondria
Mitochondrial H 2 O 2 production in mitochondria was determined by using amplex red assay. Briefly, mitochondria (0.4 mg/mL) were incubated in 96 well plate with respiration buffer, superoxide dismutase, horseradish peroxidase, succinate. Amplex red was added to the wells to start the reaction. The real-time production of H 2 O 2 was recorded using a plate reader at 555/581 nm excitation/emission for 30 minutes at 25°C. Appropriate blanks without amplex red or mitochondrial protein are included in the assay (a detailed method is described in the online-only Data Supplement). Placental RUPP (n=6) versus NP (n=6) or renal RUPP (n=8) versus NP (n=3).
Role of Mitochondrial ROS to Cause Hypertension in Response to Placental Ischemia
To understand the role played by mitochondrial oxidative stress in causing hypertension in preeclampsia, we administered RUPP rats with mitochondrial-specific antioxidants, MitoQ or MitoTEMPO. Pregnant rats were divided into NP (n=5), NP+MitoQ (n=6) or NP+MitoTEMPO (n=3), RUPP (n=6) and RUPP+MitoQ (n=10) or RUPP+MitoTEMPO (n=5). RUPP surgery was performed on gestational day 14 and MitoQ (500 μmol/L, oral gavage) or MitoTEMPO (1 mg/kg per day, osmotic pumps) was administered to the respective groups. The doses for MitoQ (500 µmol/L) and MitoTEMPO (1 mg/ kg per day) were selected based on previously published rodent studies using these antioxidants. [18] [19] [20] On gestational day 18, carotid catheters were inserted and mean arterial blood pressure was measured on gestational day 19. MitoQ was received as a gift sample from Dr Mike Murphy, University of Cambridge. MitoTEMPO was purchased from Enzo Life Sciences (ALx-430-150-M005). We measured the effect of MitoQ or MitoTEMPO on fetal outcomes by reporting the pup weight, placental weight, and litter size. Furthermore, we also examined the ETC activity by measuring complex I and IV in isolated placental mitochondria from MitoQ or MitoTEMPO treated RUPP rats.
Effect of Placental Ischemia to Cause Soluble Factors That Mediate Vascular Endothelial Cell Mitochondrial ROS
Mitochondrial-specific ROS was measured using MitoSOX red. Human umbilical venous endothelial cells (HUVECs; 70% confluency) were serum starved for 4 hours before incubation with 10% experimental NP serum (n=7) or RUPP serum (n=7) or RUPP+MitoQ (n=3) or RUPP+MitoTEMPO (n=3) serum overnight, experimental serum was washed off and cells were incubated with MitoSOX red for 30 minutes at 37°C. Cells were collected and analyzed using flow cytometer with 488 nm excitation to measure oxidized MitoSOX Red in the FL2 and FL3 channels. At least 5000 events for each sample were collected and analyzed (a detailed method is described in the online-only Data Supplement).
Statistical Analysis
All data are expressed as mean±SEM. Comparisons between groups were assessed by 1 way ANOVA with Bonferroni multiple comparisons test as post hoc analysis. A value of P<0.05 was considered statistically significant. Student t test was applied when comparisons were made between 2 groups.
Results
Role of Placental Ischemia to Cause Mitochondrial Dysfunction and ROS
Mitochondrial Enrichment
WB analysis was performed to determine the purity of our isolated mitochondria using antibodies to VDAC and GAPDH Figure 1 . Reduced uterine perfusion pressure (RUPP) placental mitochondria shows impaired respiration with elevated reactive oxygen species production. Highly coupled mitochondria were isolated from placenta and oxygen consumption was measured using Oxygraph 2K. State 3 and uncoupled respiration rates are significantly reduced in RUPP (n=5) placental mitochondria vs normal pregnant (NP; n=6; A). However, there was no difference observed in basal, state 2, and state 4 respiratory rates. Moreover, respiratory control ratio (RCR; state3 /state4) was significantly reduced in RUPP (n=5) vs NP (n=6; B). RUPP (n=6) placental mitochondria shows significantly higher production of hydrogen peroxide (H 2 O 2 ; 30%-fold) compared with NP (n=6) mitochondria (C). Data are presented as mean±SEM, *P<0.05, ANOVA with Bonferroni post hoc test (A), t test (B and C).
as mitochondrial and cytoplasmic markers. WB indicate the relative enrichment of mitochondria to be pure without any or negligible cytoplasmic contamination ( Figure S1A and S1B in the online-only Data Supplement).
Effect of Placental Ischemia on ETC, Respiration and Mitochondrial ROS in Placental or Renal Mitochondria
State 3 and uncoupled respiration rates were significantly reduced in placental mitochondria of RUPP versus NP ( Figure 1A ; 283±27 versus 409±13 pmol/s per milligram; P<0.05) and (233±23 versus 298±12 pmol/s per milligram; P<0.05), respectively. We calculated the respiratory control ratio from the respiration data, an indicator of coupled mitochondria (respiratory control ratio; state 3/state 4), which was significantly reduced in RUPP versus NP ( Figure 1B ; 7±1 versus 13±1; P<0.05). Importantly, RUPP placental mitochondria showed 30%-fold increase in real-time production of H 2 O 2 compared with NP respiration ( Figure 1C) . However, the expression of the ETC complexes was not different between NP and RUPP placental mitochondria ( Figure S2 ).
Complex I and II expressions were significantly reduced in RUPP renal mitochondria versus NP (Figure 2A Figure 2C ; 623±113 versus 972±68 pmol/s per milligram; P<0.05); however, uncoupled respiration rates were not significantly different ( Figure 2D; P=0.078) . Importantly, renal mitochondria show 136%-fold increase in mitochondrial ROS in RUPP versus NP ( Figure 2E ).
Effect of Mitochondrial-Specific Antioxidants on Hypertension and Placental ETC Activity in Response to Placental Ischemia
As a therapeutic approach to target mitochondrial oxidative stress, we sought to examine the effect of the increase mitochondrial ROS on blood pressure in RUPP rats. Interestingly, MitoQ treatment lowered blood pressure in RUPP rats (Figure 3 ; 116±4 versus 126±4 mm Hg; P<0.05), whereas MitoTEMPO (1 mg/kg per day, mini-osmotic pumps) reduced blood pressure even further in RUPP rats (Figure 3 
Effect of Mitochondrial-Specific Antioxidants on Placental Ischemia-Induced Vascular Endothelial Cell Mitochondrial ROS in Response to Soluble Factors
Overnight incubation of HUVECs with 10% serum from RUPP rats show increased mitochondrial ROS production compared with the cells that were incubated with NP serum ( Figure 6A ; 7±1 versus 3±1, % gated; P<0.05). Moreover, serum from RUPPs treated with MitoQ or MitoTEMPO attenuated mitochondrial ROS compared with sera from RUPP control rats ( Figure 6A ; 0.2±0.01 or 0.57+0.2, % gated; P<0.05). These data demonstrate the beneficial effect mitochondrial antioxidants could have on fetal endothelial cell responses exposed to placental ischemic conditions.
Discussion
Mitochondrial dysfunction and ROS are associated with preeclampsia but has never been examined in an animal model of preeclampsia, which is important to better understand the contribution mitochondrial dysfunction and ROS makes to hypertension in response to placental ischemia. This is the first study to examine intact isolated mitochondrial bioenergetics in a rat model of preeclampsia and to determine whether this altered bioenergetics contributes to the pathology of placental ischemia. In our study, we report the following novel observations: (1) placental ischemia causes reduction in mitochondrial respiration, which is associated with increased mitochondrial ROS production in both placenta and kidney, (2) RUPP placental mitochondria shows reduced ETC complex activities, (3) mitochondrial antioxidants, MitoTEMPO or MitoQ, attenuate elevated blood pressure with improvement in fetal outcomes in RUPPs, and (4) HUVECs incubated with RUPP serum show increased mitochondrial ROS, which was attenuated with MitoTEMPO or MitoQ treated RUPP serum. We feel that the overall effects in the vasculature and the placenta could be synergistic to improve maternal and fetal health in pregnancies stricken by placental ischemia and further investigations into improving mitochondrial function is warranted. Our study demonstrates that improved mitochondrial function during hypertension in response to placental ischemia is an important avenue of investigations for new therapeutic options for preeclampsia.
Two major systems that could contribute to the excessive ROS generation in placenta or any other cell system are mitochondria and NADPH oxidase. The role of the latter in causing ROS production and oxidative stress in preeclampsia has been documented by various studies. [21] [22] [23] [24] [25] However, the mitochondrial role as a source of oxidative stress in preeclampsia is not well explored as there are a limited number of studies that focused on the mitochondrial involvement in the oxidative stress during preeclampsia. Placental electron microscopic ultrastructural studies reported abnormal morphology of mitochondria in preeclamptic placentas. [26] [27] [28] Another set of functional studies from different investigators documented reduced ETC activity in placental trophoblasts and HUVECs. [10] [11] [12] [13] [14] [15] [16] Comparative proteomics analysis performed by Shi et al 29 reported that 4 proteins that were upregulated and 22 that were downregulated in preeclamptic placentae compared with normotensive placentae. This analysis showed that these proteins are involved in apoptosis, fatty acid oxidation, ROS, oxidative stress, and importantly the ETC. However, no study has been performed to examine the relevance of mitochondrial-mediated oxidative stress in the context of hypertension in response to placental ischemia, as could be the case in preeclamptic pathology. However, these studies have not been performed in preeclampsia patients. Therefore, we performed such studies in the preclinical animal model of preeclampsia, the RUPP rat, which closely mimics many aspects of preeclampsia during pregnancy.
Mitochondrial respiration and ROS measurements were performed using coupled mitochondria immediately after isolation from RUPP and NP placentas and kidneys. Our data indicate a significant reduction in state 3 and uncoupled states of respiration in placental and reduced state 3 respiration in RUPP renal mitochondria versus NP mitochondria. However, there was no difference in basal, state 2 and state 4 respiration between RUPP versus NP. Although expression of the complexes were not different between RUPP versus NP placentas, there was a significant difference in complex I and complex II expression in RUPP versus NP kidney. Complex I and IV activities were reduced in RUPP versus NP placental mitochondria. Similar results on complexes have been reported by other investigators in preeclamptic placenta. 11, 13, 14 Muralimanoharan et al 30 reported the placental mitochondrial fraction from preeclamptic women showed decreased activity of ETC component, complex III with decreased expression of complex I and IV. Other studies reported alteration of antioxidant systems (superoxide dismutase, catalase, glutathione reduced/glutathione disulfide) in preeclampsia placenta. [31] [32] [33] [34] Another recent study reported that miR-128a causes reduced mitochondrial membrane potential and ATP with increased ROS and caspase activation in HTR-8/SVneo trophoblast cells. 35 MIR-210 overexpression reduced mitochondrial function in human primary trophoblasts and AntagomiR-210 (MIR-210 inhibitor) transfection prevented this respiratory deficiency. 30 These indicate that microRNA could mediate mitochondrial dysfunction and may serve as a therapeutic target in preeclampsia. Although we see impaired mitochondrial function in the RUPP placenta and kidney, we wanted to determine if this is associated with excessive mitochondrial ROS generation. Indeed, there was a 30%-and 136%-fold increase in real-time ROS production in RUPP placental and renal mitochondria versus NP, respectively. A study published by Aris et al 36 show increased production of H 2 O 2 in both serum and placenta of preeclamptic women versus NP. However, this study did not study the source of H 2 O 2 as H 2 O 2 may be produced by multiple systems in the cell. In our study, we studied the role of mitochondria as a source of H 2 O 2 and oxidative stress in preeclamptic pathology. Overall, our respiration and ROS data indicate the mitochondrial dysfunction with mitochondrial oxidative stress in the placenta and kidney. Our current study along with other published studies indicate a mitochondrial dysfunction in placenta in response to placental ischemia, which may ultimately lead to mitochondrial oxidative stress with reduced bioenergetics in the placental cell. Moreover, we have also shown renal mitochondrial dysfunction, which may explain the link between mitochondrial oxidative stress and hypertension as the kidney plays a crucial role in blood pressure regulation.
Ischemic placenta has been shown to release soluble circulating factors, such as sFlt-1 (soluble fms-like tyrosine kinase 1), inflammatory cytokines, and AT1-AAs. Brownfoot et al 37 reported Metformin, a known mitochondrial complex I inhibitor, reduced the secretion of sFlt-1 and s-Eng (s-endoglin) from primary endothelial cells, villous cytotrophoblast cells, and preterm preeclamptic placental villous explants. This is the first study to link mitochondria with sFlt-1 and s-Eng, 2 important contributors in the pathology of preeclampsia. Another study reported the inverse correlation between sFlt-1 and mitochondrial complex IV activity in preeclamptic placenta.
14 These studies suggest that placental circulating factor, sFlt-1, may be damaging the mitochondria both within and extra placental cell types, such as endothelial cells. Recently, McCarthy et al 38 reported that MitoTEMPO reduces mitochondrial superoxide production in HUVECs treated with 3% preeclampsia plasma. A study published by Tang et al 39 show that treating JEG-3 cells (human trophoblast-like cells), with H 2 O 2 causes ROS production and reduces mitochondrial membrane potential. Collectively, these studies indicate the importance of circulating factors to contribute to endothelial oxidative stress. Therefore, we wanted to examine the effect of circulating factors stimulated in response to placental ischemia to cause endothelial oxidative stress. Experimental media containing sera from RUPP rats show increased mitochondrial ROS generation compared with media containing sera from NP control rats. Moreover, when we exposed HUVECs to sera from RUPPs treated with either mitochondrial antioxidant, MitoTEMPO, or MitoQ attenuated HUVEC mitochondrial ROS indicating that circulating factors stimulated in response to placental ischemia could cause mitochondrial dysfunction in endothelial cells in the peripheral vasculature and that mitochondrial-specific treatments can improve vascular function.
Antioxidants vitamin C and vitamin E, clinical trials failed as there was no therapeutic benefit among preeclampsia women. 40, 41 This could be because of inability of these compounds to penetrate mitochondrial membranes to target mitochondrial-mediated oxidative stress. Popova et al 42 reported a reduced blood pressure with improved placental mitochondrial function by sulodexide, an anticoagulant drug, in an experimental rat model of preeclampsia. Moreover, a few other studies documented the beneficial effect of selenium in preventing mitochondrial oxidative stress in vitro and in vivo models of preeclampsia. [43] [44] [45] In our study, as an attempt to therapeutically target mitochondrial oxidative stress, we treated RUPP rats with mitochondrial antioxidants, MitoQ, and MitoTEMPO. Administration of either drug normalized blood pressure in RUPP rats indicating the importance of improving mitochondrial ROS on hypertension in pregnancies associated with placental ischemia. These treatments are associated with improved fetal weights in addition to improvement in hypertension, which highlight the beneficial role of targeted mitochondrial antioxidants in both mother and fetus. Although these drugs only slightly improve complex I and IV in the placenta, these improvements were associated with significantly improved fetal and placental weights. Renal mitochondria were not processed for complex activity at the time of harvest and were saved for other molecular analysis to determine the effect of mitochondrial antioxidants on renal specific vasoactive pathways for future studies. However, the vast improvement in blood pressure suggests improve renal cell function. In combination with the improved mitochondrial ROS in endothelial cells, these data highlight the importance of protecting mitochondrial function for both maternal and fetal health during pregnancy. In summary, these findings indicate the importance of mitochondrial oxidative stress in the hypertension in preeclampsia and suggest the importance of improving this function of this pathway as potential treatments for this disease.
Overall, our study supports a role for placental ischemia to cause mitochondrial oxidative stress and that this form of mitochondrial ROS causes endothelial oxidative stress and elevations in blood pressure in RUPP model of preeclampsia. Antioxidants targeting mitochondria, MitoQ/MitoTEMPO, may serve as a therapeutic intervention in the management of preeclampsia. Moreover, targeting pathways that lead to mitochondrial demise may be crucial to elucidating new treatment modalities to improve clinical management of preeclampsia. Further studies are needed to understand whether mitochondrial antioxidant treatment is a therapeutic option in preeclampsia pathology or whether targeting the causal factors of mitochondrial demise is of greater overall benefit to the mother and babies affected by preeclampsia.
Perspectives
This study shows the evidence for the role of mitochondrial oxidative stress in placental ischemia. Mitochondrial antioxidants, MitoQ, and MitoTEMPO improved blood pressure and fetal weight in RUPP model, which indicates that targeting mitochondrial oxidative stress may be a therapeutic benefit. However, this study lacks specific mechanisms causing mitochondrial demise in response to placental ischemia. This will be further explored in our continued investigation into the role of mitochondrial dysfunction in course of preeclampsia.
